Glycoprotein E (VZV) Molekülinformation
Molecule Name
Envelope (E) protein
Molekülalias
gE
Drug Development Progress
Anzahl der klinischen Arzneimittel2
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
gE-1，Envelope glycoprotein E，gE
Produktanfrage
FAQ
What should be matched before selecting a gE assay?
Check species, assay purpose, antigen format, and whether the readout is antigen detection or antibody titer.
Does the gE kit measure viral load?
The listed kits are antibody or antigen ELISA tools; they are not described as viral-load assays.
Can VZV gE reagents support vaccine research?
Yes. Recombinant gE, antigen ELISA kits, and antibody-titer kits support distinct antigen-characterization and immune-response endpoints.
Which antibody reagents are included?
Available options include anti-gE monoclonal antibodies, including an unconjugated and a biotinylated format.
Is a biotinylated gE protein available?
GLE-V82E3 is biotinylated VZV gE with His and AviTag.
Which gE assay kits are available?
Available options include VZV gE ELISA kits and mouse or human anti-VZV IgG-titer serology kits.
Why is VZV gE relevant to antibody research?
gE is an abundant, immunogenic glycoprotein on virus and infected-cell surfaces, making it relevant to antigen-specific antibody studies.
Which VZV gE antigen is available?
The portfolio includes gE from varicella-zoster virus strain Oka vaccine, expressed as a His-tagged recombinant protein.
Asset Licensing Opportunity
Resources
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| LHF-535 | LHF-535; LHF-535-SDD | Phase 1 Clinical | Kineta Inc | Details | |
| SAR-440894 | SAR-440894 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | Chikungunya Fever | Details |
Customer Reviews